FY2025 · ended Dec 31, 2025 · Revenue $4.01M, -58.9% YoY · Filed Mar 13, 2026
CervoMed Inc. (CRVO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.0 million and a net loss of $27.0 million.
Revenue (TTM)
$331,295
-95.7% vs year-ago TTM
Net income (TTM)
$-30.35M
-34.2% vs year-ago TTM
Operating cash flow (TTM)
$-27.98M
-20.0% vs year-ago TTM
Free cash flow
$-12.78M
-18.7% vs prior year
EPS
$2,038,891.00
+4.7% vs prior year
Dividend per share
None
Shares outstanding
9.26M
+6.4% vs prior year
Net cash
$37.31M
FY 2021
Operating margin
-9407.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053691
- Former names
- Diffusion Pharmaceuticals Inc. (until Aug 14, 2023); RestorGenex Corp (until Jan 14, 2016); Stratus Media Group, Inc (until Mar 7, 2014); FERIS INTERNATIONAL, INC. (until Jul 16, 2008); TITAN MOTORCYCLE CO OF AMERICA INC (until Feb 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | — | — |
| Operating income | -$28.3M | -$18.2M | -$7.8M | -$3.5M | -$24.7M |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M | -$24.1M |
| Diluted EPS | — | — | — | $2,038,891.00 | $1,946,859.00 |
| Operating cash flow | -$23.4M | -$16.5M | -$7.4M | -$2.6M | -$14.5M |
| Total assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M |
| Total liabilities | $4.7M | $3.9M | $2.6M | $13.2M | $2.9M |
| Stockholders' equity | $18.2M | $39.2M | $7.4M | -$33.3M | $34.9M |
| Cash and investments | $20.9M | $38.9M | $7.8M | $16.5M | $37.3M |
| Total debt | — | — | — | — | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 10, 2026 |
All 1000 CervoMed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.